Sanofi, CVS Health, Others Accused of Insulin Price Fixing

March 20, 2017, 9:48 PM

The leading U.S. drugmakers and pharmacy benefit managers colluded to fix prices for insulin, leading to skyrocketing costs and windfall profits for the companies, a new lawsuit alleges (Boss v. CVS Health Corp., D.N.J., No. 2:17-cv-01823, complaint filed 3/17/17).

Some of the biggest players in the American health-care industry are targeted in the 69-count class action complaint, filed March 17 in a federal court in New Jersey. Drug manufacturers Sanofi-Aventis, Novo Nordisk and Eli Lilly are included. Also named are the country’s three largest pharmacy benefit managers—CVS Health, Express Scripts and OptumRx—which together control 80 percent of the ...

To read the full article log in. To learn more about a subscription click here.